{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T05:37:59Z","timestamp":1735882679226,"version":"3.32.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019899","name":"Kementerian Keuangan Republik Indonesia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019899","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>This study describes the seroconversion and serodynamics of IgG antibodies against the RBD of SARS-CoV-2 in the general population of Sleman District, Yogyakarta Special Province. We aim to identify possible factors that correlate with the seroconversion and serodynamics of IgG antibodies against the RBD of SARS-CoV-2.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We performed a longitudinal study of the population at Health and Demographic Surveillance System (HDSS) Sleman, Yogyakarta, Indonesia. Study subjects were recruited between April and December 2021 using convenience sampling and were followed up 2 times, i.e. 4\u20135 and 8\u20139 weeks. The inclusion criteria for subjects were age \u2265 18 years, absence of flu-like symptoms, and negative COVID-19 by using GeNose C19<jats:sup>\u00ae<\/jats:sup> screening. A community-based survey on demographics, comorbidities and smoking habits were documented at baseline, while a history of vaccination, COVID-19-related symptoms, mobility, and preventive measures, weight and height as well as a venous blood draw, were collected at each visit. The anti-RBD-SARS-CoV-2 IgG antibody concentration from blood plasma was measured using chemiluminescent microplate immunoassay (CMIA). Descriptive analysis was performed based on IgG seropositivity by using chi-squared test or Fisher\u2019s exact test, as appropriate. Logistic regression was subsequently performed to identify factors that were correlated with IgG seropositivity. Further, a grouping of subjects based on IgG seropositivity was done to analyze factors that might correlate with seroconversion and serodynamics of anti-RBD-SARS-CoV-2 IgG antibody. A P value \u2264 0.05 was considered to indicate a significant difference.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Three hundred eighty-five (385) participants were analyzed. At baseline, 307 out of 385 (79.7%) subjects were seropositive for the IgG antibody against the RBD of SARS-CoV-2. Descriptive analysis showed that sex, marital status, smoking habits, obesity, vaccination status, and preventive measures were different between the IgG anti-RBD-SARS-CoV-2 seropositive and negative individuals (p\u2264 0.05). Further analysis showed that, vaccination was the factor most strongly correlated with seropositivity [OR = 20.58; 95% CI 10.82, 39.15]. Based on the correlation, we separated subjects into 4 groups. Group 1 (seronegative-unvaccinated individuals; 50 subjects); Group 2 (seronegative-vaccinated individuals; 27 subjects); Group 3 (seropositive-unvaccinated individuals; 25 subjects); and Group 4 (seropositive-vaccinated individuals; 282 subjects). During monitoring, 27\/49 (55.10%), 5\/25 (20%), 9\/22 (40.91%), and 27\/257 (10.51%) of subjects in Group 1, 2, 3, and 4 respectively, received 1 or 2 doses of COVID19 vaccine. When comparing seroconversion at baseline and monitoring 2, positive IgG seroconversion was observed in Group 1 (from 0\/51 (0%) to 23\/49 (46.94%)) and Group 2 (from 0\/27 (0%) to 10\/25 (40%)), but negative seroconversion was observed in Group 4 (from 282\/0 (100%) to 248\/257 (96.50%)); while, all subjects in Group 3 remained seropositive at the end of monitoring. This evidence suggested for hybrid immunity, on which infection and vaccine simultaneously contributes to anti-RBD-SARS-CoV-2 IgG seroconversion.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>A high seroprevalence of the IgG antibody against RBD-SARS-CoV-2 in the Sleman population was found to correlate with COVID-19 vaccination and as infection occurred, thus enhancing hybrid immunity. We also identified nonresponder and rapid antibody decaying individuals, that call for targeted vaccinations in addition to annual universal boosting.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0316360","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T19:17:39Z","timestamp":1735845459000},"page":"e0316360","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Seroconversion and dynamics of IgG anti-SARS-CoV-2 antibodies during the pandemic: A two-month observation cohort study on the population of Sleman in Indonesia"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2650-1941","authenticated-orcid":true,"given":"Jajah","family":"Fachiroh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2665-1736","authenticated-orcid":true,"given":"Septi Kurnia","family":"Lestari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6759-8658","authenticated-orcid":true,"given":"Dewi Kartikawati","family":"Paramita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-8429","authenticated-orcid":true,"given":"Bagas Suryo","family":"Bintoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-6970","authenticated-orcid":true,"given":"Fatwa Sari Tetra","family":"Dewi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5146-8162","authenticated-orcid":true,"given":"Lutfan","family":"Lazuardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cici Permata","family":"Rusadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erti Nur","family":"Sagenah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7462-7904","authenticated-orcid":true,"given":"Eggi","family":"Arguni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"pone.0316360.ref001","author":"WHO","year":"2023","journal-title":"COVID-19 dashboard [Internet]."},{"issue":"11","key":"pone.0316360.ref002","doi-asserted-by":"crossref","first-page":"e1004107","DOI":"10.1371\/journal.pmed.1004107","article-title":"Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: a systematic review and meta-analysis of standardized population-based studies.","volume":"19","author":"I Bergeri","year":"2022","journal-title":"PLOS Med."},{"issue":"3","key":"pone.0316360.ref003","doi-asserted-by":"crossref","first-page":"e0248918","DOI":"10.1371\/journal.pone.0248918","article-title":"Antibody kinetics and clinical course of COVID-19 a prospective observational study.","volume":"16","author":"A Bl\u00e4ckberg","year":"2021","journal-title":"PLOS ONE"},{"issue":"1","key":"pone.0316360.ref004","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1017\/ice.2020.368","article-title":"Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge.","volume":"42","author":"P Nori","year":"2021","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"pone.0316360.ref005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12929-020-00703-5","article-title":"Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications","volume":"28","author":"IP Trougakos","year":"2021","journal-title":"J Biomed Sci"},{"issue":"6","key":"pone.0316360.ref006","doi-asserted-by":"crossref","first-page":"e00482","DOI":"10.1128\/jcm.00482-21","article-title":"Immunity to SARS-CoV-2: what do we know and should we be testing for it?","volume":"60","author":"A Misra","year":"2022","journal-title":"J Clin Microbiol"},{"issue":"5","key":"pone.0316360.ref007","doi-asserted-by":"crossref","first-page":"e0251234","DOI":"10.1371\/journal.pone.0251234","article-title":"Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia.","volume":"16","author":"NLA Megasari","year":"2021","journal-title":"PLOS ONE"},{"issue":"3","key":"pone.0316360.ref008","doi-asserted-by":"crossref","first-page":"169","DOI":"10.21109\/kesmas.v17i3.6070","article-title":"SARS-CoV-2 antibody seroprevalence in Jakarta, Indonesia.","volume":"17","author":"I Ariawan","year":"2022","journal-title":"Kesmas J Kesehat Masy Nas."},{"issue":"6","key":"pone.0316360.ref009","doi-asserted-by":"crossref","first-page":"e0000698","DOI":"10.1371\/journal.pgph.0000698","article-title":"Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency in March-April 2021, Yogyakarta, Indonesia.","volume":"3","author":"RA Ahmad","year":"2023","journal-title":"PLOS Glob Public Health."},{"issue":"11","key":"pone.0316360.ref010","doi-asserted-by":"crossref","first-page":"e1508","DOI":"10.1016\/S2214-109X(21)00355-7","article-title":"High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.","volume":"9","author":"P Lalwani","year":"2021","journal-title":"Lancet Glob Health."},{"issue":"8","key":"pone.0316360.ref011","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.3390\/cells10081952","article-title":"Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccination.","volume":"10","author":"A Tretyn","year":"2021","journal-title":"Cells"},{"issue":"1","key":"pone.0316360.ref012","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/s41467-021-21444-5","article-title":"Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19.","volume":"12","author":"AK Wheatley","year":"2021","journal-title":"Nat Commun."},{"issue":"5","key":"pone.0316360.ref013","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","article-title":"Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression","volume":"23","author":"N Bobrovitz","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"pone.0316360.ref014","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection","volume":"386","author":"V Hall","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"pone.0316360.ref015","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1056\/NEJMc2302462","article-title":"Durability of bivalent boosters against Omicron subvariants","volume":"388","author":"DY Lin","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0316360.ref016","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of Protection against mild and severe disease by Covid-19 vaccines","volume":"386","author":"N Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0316360.ref017","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1473-3099(22)00140-2","article-title":"Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study","volume":"22","author":"T Cerqueira-Silva","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"pone.0316360.ref018","doi-asserted-by":"crossref","first-page":"e0272690","DOI":"10.1371\/journal.pone.0272690","article-title":"Two- years antibody responses following SARS-CoV-2 infection in humans: A study protocol","volume":"17","author":"E Arguni","year":"2022","journal-title":"PLoS ONE"},{"key":"pone.0316360.ref019","author":"Sleman District Health Office","year":"2021","journal-title":"Info seputar vaksin COVID-19\u2014Dinas Kesehatan Sleman [Internet]."},{"issue":"1","key":"pone.0316360.ref020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41746-022-00661-2","article-title":"Fast and noninvasive electronic nose for sniffing out COVID-19 based on exhaled breath-print recognition.","volume":"5","author":"DK Nurputra","year":"2022","journal-title":"NPJ Digit Med"},{"issue":"7","key":"pone.0316360.ref021","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/1403494817717557","article-title":"Designing and collecting data for a longitudinal study: the Sleman Health and Demographic Surveillance System (HDSS).","volume":"46","author":"FST Dewi","year":"2018","journal-title":"Scand J Public Health"},{"key":"pone.0316360.ref022","doi-asserted-by":"crossref","first-page":"100348","DOI":"10.1016\/j.lansea.2023.100348","article-title":"Characteristics and clinical outcomes of patients with pre-delta, delta and omicron SARS-CoV-2 infection in Indonesia (2020\u20132023): a multicentre prospective cohort study.","volume":"22","author":"A Karuniawati","year":"2024","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"pone.0316360.ref023","doi-asserted-by":"crossref","first-page":"n1815","DOI":"10.1136\/bmj.n1815","article-title":"Covid-19: Indonesia becomes Asia\u2019s new pandemic epicentre as delta variant spreads","volume":"374","author":"O. Dyer","year":"2021","journal-title":"BMJ"},{"issue":"36","key":"pone.0316360.ref024","doi-asserted-by":"crossref","first-page":"13216","DOI":"10.12998\/wjcc.v10.i36.13216","article-title":"Case series in Indonesia: B.1.617.2 (delta) variant of SARS-CoV-2 infection after a second dose of vaccine.","volume":"10","author":"A Karuniawati","year":"2022","journal-title":"World J Clin Cases"},{"key":"pone.0316360.ref025","author":"WHO","year":"2021","journal-title":"Update on Omicron [Internet]."},{"key":"pone.0316360.ref026","unstructured":"COVID-19 data. Available from: https:\/\/m.andrafarm.com\/_andra.php?_i=daftar-co19-provinsi&_en=ENGLISH&urut=2&asc=00100000000. Accessed November 2023."},{"issue":"4","key":"pone.0316360.ref027","doi-asserted-by":"crossref","first-page":"e734","DOI":"10.1111\/tbed.14344","article-title":"Analysis of IgG, IgA and IgM antibodies against SARS-CoV-2 spike protein S1 in convalescent and vaccinated patients with the Pfizer-BioNTech and CanSinoBio vaccines.","volume":"69","author":"EA Melgoza-Gonz\u00e1lez","year":"2022","journal-title":"Transbound Emerg Dis."},{"issue":"2","key":"pone.0316360.ref028","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial.","volume":"21","author":"Y Zhang","year":"2021","journal-title":"Lancet Infect Dis."},{"issue":"5","key":"pone.0316360.ref029","doi-asserted-by":"crossref","first-page":"2088966","DOI":"10.1080\/21645515.2022.2088966","article-title":"Antibody response to SARS-CoV-2 vaccines among hospitalized patients in China: a case-control study.","volume":"18","author":"FP Li","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"pone.0316360.ref030","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/vaccines11061045","article-title":"A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations.","volume":"11","author":"L Hu","year":"2023","journal-title":"Vaccines (Basel)."},{"issue":"12","key":"pone.0316360.ref031","doi-asserted-by":"crossref","first-page":"e0261931","DOI":"10.1371\/journal.pone.0261931","article-title":"Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia.","volume":"16","author":"O Herlinda","year":"2021","journal-title":"PloS One"},{"key":"pone.0316360.ref032","doi-asserted-by":"crossref","first-page":"100547","DOI":"10.1016\/j.lanepe.2022.100547","article-title":"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study","volume":"24","author":"ME Zaballa","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"11","key":"pone.0316360.ref033","doi-asserted-by":"crossref","first-page":"001692","DOI":"10.1099\/jgv.0.001692","article-title":"Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples","volume":"102","author":"A Szymczak","year":"2021","journal-title":"J Gen Virol"},{"issue":"2","key":"pone.0316360.ref034","doi-asserted-by":"crossref","first-page":"e0059021","DOI":"10.1128\/Spectrum.00590-21","article-title":"Kinetics of SARS-CoV-2 specific and neutralizing antibodies over seven months after symptom onset in COVID-19 patients.","volume":"9","author":"L Zhu","year":"2021","journal-title":"Microbiol Spectr."},{"key":"pone.0316360.ref035","doi-asserted-by":"crossref","first-page":"300","DOI":"10.12688\/f1000research.109676.1","article-title":"Waning anti-SARS-CoV-2 receptor-binding domain total antibody in CoronaVac-vaccinated individuals in Indonesia.","volume":"11","author":"H Harapan","year":"2022","journal-title":"F1000Research"},{"issue":"20","key":"pone.0316360.ref036","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/j.vaccine.2022.03.069","article-title":"Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: implications for vaccine strategies","volume":"40","author":"MA Sughayer","year":"2022","journal-title":"Vaccine"},{"issue":"12","key":"pone.0316360.ref037","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1001\/jama.1988.03410120080031","article-title":"Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine","volume":"260","author":"JY Weissman","year":"1988","journal-title":"JAMA"},{"issue":"7","key":"pone.0316360.ref038","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/annrheumdis-2021-221554","article-title":"Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease","volume":"81","author":"D Simon","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0316360.ref039","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","article-title":"SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact","volume":"22","author":"M Lipsitch","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"pone.0316360.ref040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamainternmed.2021.7024","article-title":"Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US","volume":"182","author":"J Sun","year":"2022","journal-title":"JAMA Intern Med"},{"key":"pone.0316360.ref041","doi-asserted-by":"crossref","first-page":"994173","DOI":"10.3389\/fimmu.2022.994173","article-title":"Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination.","volume":"13","author":"M Sister\u00e9-Or\u00f3","year":"2022","journal-title":"Front Immunol."},{"issue":"6","key":"pone.0316360.ref042","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-specific humoral and cellular Immunity in COVID-19 convalescent individuals","volume":"52","author":"L Ni","year":"2020","journal-title":"Immunity"},{"issue":"7","key":"pone.0316360.ref043","doi-asserted-by":"crossref","first-page":"e1306","DOI":"10.1002\/cti2.1306","article-title":"SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation.","volume":"10","author":"JT Sandberg","year":"2021","journal-title":"Clin Transl Immunol."},{"key":"pone.0316360.ref044","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.eclinm.2023.101965","article-title":"Vaccines and therapeutics for immunocompromised patients with COVID-19.","volume":"59","author":"S Shoham","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T19:17:54Z","timestamp":1735845474000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316360"}},"subtitle":[],"editor":[{"given":"Paul V.","family":"Licciardi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0316360","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]}}}